Fitzgerald Meghan

Director Meghan Fitzgerald sells 70.0K shares at $27.45 for $1.9M, reducing holdings 62.0%

Director Meghan Fitzgerald sold 70,000 shares at $27.45 on 2026-03-26, reducing her position from 112,963 shares to 42,963 shares—a 62.0% reduction in holdings. The sale occurred near the 52-week high of $29.72, just 11.1% below peak, and at a 4.0% premium to the current price of $26.41. However, context is troubling: Roivant Sciences reported quarterly revenue of $2.0M against a net loss of $265.9M, with annual revenue declining 76.7% year-over-year, and the company remains unprofitable. Across her cross-ticker trading history, Fitzgerald's prior sells showed a 0.00% well-timed rate—meaning her previous exit points were followed by positive returns, indicating she sold before gains materialized. The substantial reduction in exposure during a period of severe operational deterioration and against a backdrop of poorly-timed historical sells warrants investor scrutiny.

Director Meghan Fitzgerald sold 20,000 THC shares at $146.34; post-sale holdings fall to 15,269 shares (-56.7%)

Director Meghan Fitzgerald sold 20,000 shares of Tenet Healthcare at $146.34 on 2024-08-06, reducing her holdings from 35,269 shares to 15,269 shares. The sale occurred at a price that is -1.8% from the 52-week high of $152.87, and the stock has since risen 14.6% over 30 days and 18.1% over 90 days. Tenet Healthcare shows solid operational fundamentals with $5,103,000,000.00 in quarterly revenue, $477,000,000.00 in net income, and annual revenue growth of 7.2%, supported by a low P/E of 4.07. The sale represents a material reduction in the director's stake—a 56.7% decrease in holdings—though the transaction occurs within a context of strong recent stock performance and adequate financial health at the company.